Bone Biologics Corp (BBLG) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bone Biologics Corp on December 21, 2022, reporting an event that occurred on December 18, 2022. The company is incorporated in Delaware and its common stock and warrants trade on The Nasdaq Stock Market LLC under the symbols BBLG and BBLGW, respectively.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance event and does not contain financial statements or performance data.
Material Changes
Effective December 18, 2022, Stephen LaNeve resigned as a director of the Company. The filing explicitly states that the resignation was not the result of any disagreement with the Company regarding its operations, policies, or practices.
Management Commentary and Risks
Management expressed appreciation for Mr. LaNeve's years of service. No guidance, outlook, risks, contingencies, or unusual items were disclosed in this specific filing.
Key Facts for Investor Verification
- Stephen LaNeve resigned as a director effective December 18, 2022.
- The resignation was voluntary and not due to any disagreement with the company.
- No financial data or operational updates were included in this report.